Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Liposomal Doxorubicin: Effective Treatment For Pediatric Desmoid Fibromatosis

P. Ananth, Annette M Werger, S. Voss, C. Rodríguez-Galindo, K. Janeway
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Efficacy of liposomal doxorubicin (LD) in treating desmoid fibromatosis (DF) in children has not been well evaluated. This retrospective case series examines five children with progressive DF, treated with LD. We report progression‐free intervals (PFIs) and radiographic as well as clinical responses for each medication received. LD was well tolerated, with an average 4.5% reduction in tumor size and median PFI of 29 months. Treatment with LD conferred the longest PFI of all medical therapies pursued. Thus, LD is an important treatment option for DF in pediatrics.
This paper references
10.1016/J.YDER.2011.01.021
Aggressive Fibromatosis in Children and Adolescents: The Italian Experience
A. Zaenglein (2011)
10.1002/cncr.24679
Aggressive fibromatosis in children and adolescents
C. Meazza (2010)
10.1016/S0360-3016(00)00566-6
Long-term results with radiation therapy for pediatric desmoid tumors.
T. Merchant (2000)
10.1093/ANNONC/MDS298
The treatment of desmoid tumors: a stepwise clinical approach.
S. Bonvalot (2012)
Safety and efficacy of highdose tamoxifen and sulindac for desmoid tumor in children: results of a Children’s Oncology Group (COG) phase II study
SX Skapek (2013)
10.1159/000081337
Response of Progressive Fibromatosis to Therapy with Liposomal Doxorubicin
G. Wehl (2004)
10.1097/MPH.0b013e3182678d25
Hydroxyurea Treatment Can Avoid the Need for Aggressive Surgery in Pediatric Fibromatosis
G. Bisogno (2013)
10.1200/JCO.2010.33.5489
Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation.
S. Salas (2011)
SUPPORTING INFORMATION Additional Supporting Information may be found online in the supporting information tab for this article
10.1158/1078-0432.CCR-10-1177
Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial
R. Chugh (2010)
Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis. Pediatric Blood & Cancer
P Ananth (2017)
10.1016/j.ejca.2008.06.038
Multimodality treatment of mesenteric desmoid tumours.
M. Bertagnolli (2008)
10.1200/JCO.2006.08.2966
Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial.
S. Skapek (2007)
10.1093/annonc/mdr051
Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG).
D. Garbay (2012)
10.1093/annonc/mdq341
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.
N. Penel (2011)
10.1016/j.ejca.2009.08.016
Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.
A. Constantinidou (2009)
10.1016/j.ejca.2008.10.026
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E. Eisenhauer (2009)
10.1148/rg.335125214
Response criteria in oncologic imaging: review of traditional and new criteria.
T. Tirkes (2013)
10.1002/pbc.24457
Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study
S. Skapek (2013)
10.1016/j.jpedsurg.2012.10.017
Desmoid fibromatosis in children and adolescents: a conservative approach to management.
Joshua N. Honeyman (2013)
10.1158/1078-0432.CCR-10-3322
Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis
M. Gounder (2011)
10.1002/JSO.10104
Desmoid tumors: A novel approach for local control
C. Baliski (2002)
10.1002/14651858.CD005006.pub3
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
E. C. van Dalen (2006)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar